Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

603
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
603
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurokinin-1 receptor activation protects against cardiac fibrosis, inflammation and diastolic dysfunction in type 2 diabetic mice.

British journal of pharmacology·2026
Same author

Polypharmacy in mice disrupts left ventricular function and structure and promotes proteome reorganisation in an age- and sex-specific fashion.

British journal of pharmacology·2025
Same author

IgE and cardiac disease.

Acta physiologica (Oxford, England)·2025
Same author

The orphan nuclear receptor Nr4a1 contributes to interstitial cardiac fibrosis via modulation of cardiac fibroblast and macrophage phenotype.

Cellular and molecular life sciences : CMLS·2024
Same author

Cellular metabolism of substance P produces neurokinin-1 receptor peptide agonists with diminished cyclic AMP signaling.

American journal of physiology. Cell physiology·2024
Same author

Replacement substance P reduces cardiac fibrosis in monkeys with type 2 diabetes.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2023

Related Experiment Video

Updated: Dec 29, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.3K

The Diabetic Cardiac Fibroblast: Mechanisms Underlying Phenotype and Function.

Scott P Levick1,2, Alexander Widiapradja1,2

  • 1Kolling Institute for Medical Research, Royal North Shore Hospital, St Leonards 2065, Australia.

International Journal of Molecular Sciences
|February 7, 2020
PubMed
Summary

Diabetic cardiomyopathy causes heart remodeling, including fibrosis, through cardiac fibroblasts. This review explores how high glucose affects these cells and identifies potential opposing molecules.

Keywords:
diabetesdiabetic cardiomyopathyfibrosishearthigh glucose

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.5K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

502

Related Experiment Videos

Last Updated: Dec 29, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.3K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.5K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

502

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Cell Biology

Background:

  • Diabetic cardiomyopathy is a key complication of diabetes, characterized by heart remodeling.
  • Cardiac fibrosis, driven by cardiac fibroblasts, significantly contributes to diastolic dysfunction and heart failure with preserved ejection fraction.
  • Understanding the role of cardiac fibroblasts in diabetes is crucial for therapeutic development.

Purpose of the Study:

  • To review the cardiac fibroblast phenotype under high-glucose conditions mimicking diabetes.
  • To elucidate the molecular pathways driving fibroblast activation in a diabetic milieu.
  • To identify molecules that may counteract the pro-fibrotic effects of high glucose on cardiac fibroblasts.

Main Methods:

  • Focus on studies utilizing isolated cardiac fibroblasts.
  • Analysis of existing literature on high-glucose-induced changes in cardiac fibroblast behavior.
  • Identification and discussion of signaling pathways involved in fibroblast activation.

Main Results:

  • High-glucose conditions induce a pro-fibrotic phenotype in cardiac fibroblasts.
  • Specific molecular pathways mediate these high-glucose-induced changes.
  • Several molecules show potential to inhibit high-glucose-induced fibroblast activation.

Conclusions:

  • Cardiac fibroblasts are central effectors in diabetic cardiomyopathy-associated fibrosis.
  • Targeting fibroblast responses to high glucose presents a therapeutic avenue.
  • Further research is needed to identify and validate molecules that oppose pro-fibrotic actions.